

Background

This policy, which was written by the Scottish Antimicrobial Prescribing Group (SAPG) based upon NHS Greater Glasgow and Clyde guidance and adapted for use within Ayrshire and Arran, covers the use of intravenous (IV) gentamicin in adults.

The policy is for the use of gentamicin for the treatment of infection only. Recommendations on gentamicin dosing for surgical prophylaxis etc. are provided in separate guidelines on AthenA.

The guidance **does not apply** to gentamicin use in the following:

- o synergistic treatment of endocarditis or *Staphylococcal* bone infection
- o patients treated in Renal units or receiving haemodialysis or haemofiltration
- major burns
- o ascites
- o age < 16 years
- cystic fibrosis

Contra-indications and cautions

- Contra-indications to gentamicin therapy hypersensitivity, myasthenia gravis
- Cautions to gentamicin therapy:
 - Patients with decompensated liver disease aminoglycosides are associated with an increased risk of renal failure.
 - Concurrent administration of neurotoxic and / or nephrotoxic agents increases the risk of gentamicin toxicity. Review therapy and consider amending or withholding nephrotoxic drugs during gentamicin treatment. Avoid co-administration with the following:
 - neuromuscular blockers
 - other potentially nephrotoxic (e.g. NSAIDs and ACE Inhibitors) or ototoxic drugs
 - potent diuretics
 - other aminoglycosides

This list is not exhaustive – consult the Summary of Product Characteristics (eSPC) for a full list (www.medicines.org.uk)

- Chronic Kidney Disease (CKD) Stage 4 or more, known or suspected acute kidney injury in the previous 48 hours (≥ 50% increase in baseline serum creatinine or oliguria > 6 hours). If gentamicin is clinically indicated, give one dose as per guidance and check with microbiology or an infection specialist before giving a second dose.
- Pregnancy use booking weight instead of actual weight.

Prescribing and documentation

- The NHS Ayrshire and Arran gentamicin prescription chart must be used when gentamicin is prescribed as per this guideline, "IV gentamicin in adults ≥16 years old."
- The charts should be used for prescribing treatment doses of gentamicin in conjunction with the existing inpatient prescribing chart (e.g. kardex or electronic prescribing) and medical/nursing documentation.
- These charts contain a step-wise approach to safe and effective prescribing and key points of advice on monitoring, interpreting and re-prescribing.
- An antimicrobial app and/or online calculator is available and should be used to calculate the initial gentamicin dose.


Reference: ADTC 189/04 Supersedes: ADTC 189/3 Page 1 of 5
Written by: KA Calder and K Hamilton on behalf of the Antimicrobial Management Team (AMT)
Date written: July 2021 Date approved by AMG: 27th August 2021 Review date: August 2024



STEP 1: Calculate, prescribe and administer the first dose

- To reduce the risk of mortality, commence gentamicin administration within 1 hour of recognising sepsis.
- If creatinine is known use the online calculator or app (preferred method). The guidelines in Table 1 (below) can be used if the online calculator is not available. The dose amount and dosage interval are based on estimated creatinine clearance (Box 1) and actual body weight. In pregnancy, use booking weight.
- If creatinine is not known give an initial dose of 5 mg/kg gentamicin (maximum 400 mg) or, if Chronic Kidney Disease (CKD) 5, give 2.5 mg/kg (maximum 180 mg) on advice of senior staff. Calculate the dose using **actual** body weight. In pregnancy, use booking weight.
- Give the recommended dose by infusion in 100mL sodium chloride 0.9% over 30 minutes and ensure the time of administration is noted on the medicine chart.

Box 1: Estimation of creatinine clearance (CrCl)



Cautions:

- Use actual body weight, booking weight (pregnancy) or maximum body weight whichever is lower. For maximum body weight, see the following table: https://www.sapg.scot/media/4471/maximum-body-weight-table.pdf
- In patients with low creatinine (< 60 micromol/L), use 60 micromol/L.
- Note: Use of estimated glomerular filtration rate (eGFR) is not recommended.

Table 1: Initial GENTAMICIN doses and dose intervals

Actual body weight → Cr Cl (mL/min) ↓	40 - 49 kg	50 - 59 kg	60 - 69 kg	70 - 80 kg	> 80 kg
< 21	2.5 mg/kg (max 180 mg) then take a sample after 24 hours				
21 - 30	180 mg	200 mg	240 mg	240 mg	260 mg
	48 hourly	48 hourly	48 hourly	48 hourly	48 hourly
31 - 40	200 mg	240 mg	280 mg	300 mg	320 mg
	48 hourly	48 hourly	48 hourly	48 hourly	48 hourly
41 - 50	240 mg	280 mg	320 mg	360 mg	400 mg
	48 hourly	48 hourly	48 hourly	48 hourly	48 hourly
51 - 60	200 mg	240 mg	280 mg	300 mg	320 mg
	24 hourly	24 hourly	24 hourly	24 hourly	24 hourly
> 60	240 mg	280 mg	320 mg	360 mg	400 mg
	24 hourly	24 hourly	24 hourly	24 hourly	24 hourly

Caution: If the patient weighs < 40 kg and CrCl is \geq 21 mL/min, give a single dose of 5 mg/kg then take a sample 6 – 14 hours after the dose and follow the instructions in Step 2.

Reference: ADTC 189/04 Supersedes: ADTC 189/3 Page 2 of 5
Written by: KA Calder and K Hamilton on behalf of the Antimicrobial Management Team (AMT)
Date written: July 2021 Date approved by AMG: 27th August 2021 Review date: August 2024




Note that patients who have unusual clinical characteristics e.g. weight <40kg, weight >120kg, age >90 years may require dose adjustments and require close monitoring. Contact pharmacy for advice.

STEP 2: Monitor creatinine and gentamicin concentrations and reassess the dosage regimen

Concentrations are meaningless unless the dose & sample times are recorded accurately

If creatinine clearance is ≥ 21 mL/min

- Take a blood sample 6-14 hours after the start of the first gentamicin infusion.
- Record the exact time of all gentamicin samples on the gentamicin prescribing chart AND on the sample request form.
- Record the serum concentration on the gentamicin prescribing chart.
- Plot the concentration measurement on the graph and reassess the dose / dosing interval as indicated.
- This will indicate one of 3 options:
- 1) continue the present dosage regimen
- 2) adjust the dosage interval
- 3) withhold and resample after 24 hours



If creatinine clearance is < 21 mL/min

- Take a blood sample 24 hours after the start of the first gentamicin infusion.
- Record the exact time of all gentamicin samples using the gentamicin prescribing chart AND on the sample request form.
- If therapy is to continue, take additional blood samples at least every 24 hours and give a further dose once the measured concentration is < 1 mg/L.

Reference: ADTC 189/04 Supersedes: ADTC 189/3 Page 3 of 5
Written by: KA Calder and K Hamilton on behalf of the Antimicrobial Management Team (AMT)
Date written: July 2021 Date approved by AMG: 27th August 2021 Review date: August 2024



General points

- Document the action taken in the medical notes and on the gentamicin prescribing chart.
- Undertake pre-prescribing checks (Boxes 2 and 3) to assess the risk of renal toxicity and ototoxicity.
- Prescribe the next dose as appropriate.
- Seek advice from pharmacy or microbiology if you are unsure how to interpret the result or if the
 concentrations are very low. Doses up to 600 mg may be required in obese patients, but seek advice before
 giving doses greater than 400mg.
- If a blood sample is not taken, is lost or is taken at wrong time *and* if there is any concern about the patient's renal function, take a sample 20-24 hours after the start of the gentamicin infusion and wait for the result before giving the next dose. Otherwise, take a blood sample after the next dose.

If the measured concentration is unexpectedly HIGH or LOW, consider the following:

- Were dose and sample times recorded accurately?
- Was the correct dose administered?
- Was the sample taken from the line used to administer the drug?
- Was the sample taken during drug administration?
- Has renal function declined or improved?
- Does the patient have oedema or ascites?

If in doubt, take another sample before re-prescribing and / or contact pharmacy for advice

STEP 3: Assess daily the ongoing need for gentamicin and signs of toxicity

- Take a further blood sample 6-14 hours after the dose, at least every 2 days.
- If the gentamicin concentration is unexpectedly high or if renal function alters, daily sampling may be necessary.
- To minimise the risk of toxicity, duration of treatment should normally be limited to 72 hours. For guidance
 on treatment following 72 hours of gentamicin please refer to the following guideline: IV Gentamicin review after 72 hours of treatment.

Box 2: Renal toxicity

- Monitor creatinine daily. Seek advice if renal function unstable (e.g. change in creatinine of > 15-20%).
- Signs of renal toxicity include increase in creatinine or decrease in urine output/oliguria.
- Consider an alternative agent if creatinine is rising or the patient becomes oliguric.

Box 3: Ototoxicity

- Ototoxicity secondary to gentamicin is independent of drug concentration. It is suggested by any of the following: new tinnitus, dizziness, poor balance, hearing loss or oscillating vision.
- Toxicity is associated with prolonged aminoglycoside use (usually > 10 days but may be > 72 hours) and is secondary to drug accumulation within the inner ear.
- Multiple courses of gentamicin are also a risk factor for ototoxicity.
- Stop treatment if ototoxicity is suspected and refer to microbiology or an infection specialist for advice on future therapy.
- If gentamicin continues for > 7 days, consider referring to audiology for assessment.

Reference: ADTC 189/04 Supersedes: ADTC 189/3 Page 4 of 5
Written by: KA Calder and K Hamilton on behalf of the Antimicrobial Management Team (AMT)
Date written: July 2021 Date approved by AMG: 27th August 2021 Review date: August 2024



Bibliography

Scottish Antimicrobial Prescribing Group, Intravenous Gentamicin use in adults, Greater Glasgow and Clyde (GGC guidance) June 2019. Accessed 26th July 2021

Reference: ADTC 189/04 Supersedes: ADTC 189/3 Page 5 of 5
Written by: KA Calder and K Hamilton on behalf of the Antimicrobial Management Team (AMT)
Date written: July 2021 Date approved by AMG: 27th August 2021 Review date: August 2024